Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542628 | 0.88 | CYP19A1 (0.42) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL24023300 | 0.82 | EPHX1 (0.40) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL11991229 | 0.82 | CYP19A1 (0.47) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL9963862 | 0.80 | SMN1; SMN2 (0.38) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL5986431 | 0.79 | EPHX1 (0.40) | CYP19A1EPHX1HTTSMN1; SMN2NAAA | |
| SCHEMBL5987477 | 0.79 | EPHX1 (0.40) | CYP19A1EPHX1HTTSMN1; SMN2NAAA | |
| SCHEMBL7606345 | 0.79 | EPHX1 (0.40) | CYP19A1EPHX1HTTSMN1; SMN2NAAA | |
| SCHEMBL7371636 | 0.78 | EPHX1 (0.39) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL7371640 | 0.78 | EPHX1 (0.39) | CYP19A1EPHX1HTTSMN1; SMN2NAAA | |
| SCHEMBL13647263 | 0.78 | CYP19A1 (0.41) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2021-11-18 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | PIK3CA, AKT3, GSK3B | CYP19A1 854/4885EPHX1 1806/4885HTT 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.